Singapore markets open in 7 hours 32 minutes

NVO Jul 2024 180.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.01000.0000 (0.00%)
As of 10:07AM EDT. Market open.
Full screen
Previous close0.0100
Open0.0100
Bid0.0000
Ask0.0100
Strike180.00
Expiry date2024-07-19
Day's range0.0100 - 0.0100
Contract rangeN/A
Volume1
Open interest223
  • Yahoo Finance Video

    China chip exports, Fed rate cut optimism: Market Domination

    The tech-heavy Nasdaq Composite (^IXIC) and S&P 500 (^GSPC) are taking hits leading into the final trading hour of Wednesday, July 17, in connection to a selloff by semiconductor companies. Julie Hyman and Josh Lipton bring on the leading experts and market strategists to talk about where the market is headed and how US-China trade relations could impact growth. Yardeni Research President Ed Yardeni joins the program to discuss movements in small and mid cap stocks, touching on which direction tech sector trends could move in based on the Federal Reserve's commitment to interest rate cuts. KraneShares Managing Director David Adelman, who also served as the US ambassador to Singapore, comments on the role stricter US export controls could have on pushing China to possibly "accelerate... development of its ecosystem." Wedbush Securities SVP of equity research Matt Bryson believes the US-China trade policies won't have much effect on chipmakers like Nvidia (NVDA). Other top trending tickers on the Yahoo Finance platform include Tesla (TSLA), Charles Schwab (SCHW), JB Hunt Transport Services (JBHT), and Johnson & Johnson (JNJ) after the pharma giant reported a second-quarter beat on earnings estimates. This post was written by Luke Carberry Mogan.

  • Yahoo Finance Video

    Novo Nordisk, Eli Lilly fall on data from Roche's weight-loss pill

    Shares of Novo Nordisk (NVO) and Eli Lilly (LLY) are sliding after Roche (ROG.SW, RBO.PA) reported promising early-stage trial data from its weight-loss pill. Yahoo Finance Senior Reporter Anjalee Khemlani breaks down the trial results and how the medication may disrupt the current state of the weight-loss drug market as GLP-1 drugs like Novo Nordisk's Ozempic and Eli Lilly's Mounjaro face record demand. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl

  • Zacks

    Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data

    Shares of obesity drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY) lost market value on Wednesday after Roche (RHHBY) released positive early-stage data from a study on its obesity drug candidate.